Shanghai Fosun Pharmaceutical (600196.SH): CMC-2310 orally dissolving film approved for drug clinical trial.

07/04/2025

GMT Eight

Shanghai Fosun Pharmaceutical (600196.SH) announced that its controlling subsidiary, Shanghai Fosun Pharmaceutical (Xuzhou) Co., Ltd., has recently obtained approval from the National Medical Products Administration to conduct clinical trials for CMC-2310 orally disintegrating film for the treatment of schizophrenia in adults and patients aged 13 and above. The announcement stated that CMC-2310 is a chemically developed drug independently researched by the group, intended for the treatment of schizophrenia in adults and patients aged 13 and above. As of March 2025, the group's total research and development investment in CMC-2310 is approximately RMB 7.25 million (unaudited).

Liaoning Shenhua Holdings' (600653.SH) controlling shareholder has accumulated an additional 6.97 million shares of the company.

In the first three months of CH OVS G OCEANS (00081), cumulative contract sales totaled 6.932 billion yuan, a year-on-year decrease of 12.5%.

Contact: [email protected]

Shanghai Fosun Pharmaceutical (600196.SH): CMC-2310 orally dissolving film approved for drug clinical trial.

RECOMMEND

Cui Dongshu: The export of cars will reach a very high level by 2025, while the export of lithium-ion batteries will basically remain stable at a monthly level of $5 billion.

Goldman Sachs analyzes the logic behind the sharp drop in the US dollar: Similar to "Brexit", foreign investors are selling US stocks instead of US bonds.

National Energy Administration: As of the end of March, the cumulative installed capacity of power generation in the country reaches 3.43 billion kilowatts, a year-on-year increase of 14.6%.